专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

WO2010048268A3 MANGANESE-OXO CLUSTERS AS CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING 审中-公开
标题翻译： MANGANESE-OXO集群作为磁共振成像的对比代理
公开(公告)号：WO2010048268A3
公开(公告)日：2010-09-16
申请号：PCT/US2009061452
申请日：2009-10-21
申请人： UNIV GEORGETOWN , STOLL SARAH , MERTZMAN JULIE , VAN KOUREN EDWARD , ALBANESE CHRISTOPHER , FRICKE STANLEY
发明人： STOLL SARAH , MERTZMAN JULIE , VAN KOUREN EDWARD , ALBANESE CHRISTOPHER , FRICKE STANLEY
IPC分类号： A61K49/18 , A61K33/32 , A61K49/06
CPC分类号： A61K49/1878 , A61K49/00 , A61K49/128 , B82Y5/00
摘要： Nanoparticles for use as magnetic resonance imaging contrast agents are described. The nanoparticles are made up of a polymeric support and a manganese-oxo or manganses-iron-oxo cluster having magnetic properties suitable of a contrast agent. The manganese-oxo clusters may be Mn- 12 clusters, which have known characteristics of a single molecule magnet. The polymer support may form a core particle which is coated by the clusters, or the clusters may be dispersed within the polymeric agent.
摘要翻译：描述了用作磁共振成像造影剂的纳米颗粒。纳米颗粒由聚合物载体和具有适合造影剂的磁性能的锰 - 氧代或芒果 - 铁 - 氧代簇形成。锰 - 氧代簇可以是具有单分子磁体的已知特征的Mn-12簇。聚合物载体可以形成被簇包覆的核心颗粒，或者簇可以分散在聚合物中。

62. 发明申请

WO2010099804A1 MAGNETIC RESONANCE IMAGING OF THE LIVER 审中-公开
标题翻译：肝脏的磁共振成像
公开(公告)号：WO2010099804A1
公开(公告)日：2010-09-10
申请号：PCT/EP2009/001567
申请日：2009-03-05
申请人： CMC CONTRAST AB , JOHANSSON, Nils-Olof
发明人： JOHANSSON, Nils-Olof
IPC分类号： A61K49/06
CPC分类号： A61K49/06
摘要： Method for examination of the liver of a human patient, comprising the following sequential steps: a) providing a contrast agent comprising a physiologically acceptable non-chelate manganese (II) compound, a physiologically acceptable amino acid and a vitamin D; b) administering the contrast agent orally or gastrically to the patient; and c) subjecting the patient to magnetic resonance imaging (MRI) of the liver about 1-6 hours after administration of the contrast agent. Contrast agent as above for use in examination of the liver of a human patient by administration to the patient about 1-6 hours before subjecting the patient to MRI. Use of a physiologically acceptable non-chelate manganese (II) compound, a physiologically acceptable amino acid and a vitamin D for the manufacture of a contrast agent for examination of the liver of a human patient by administration to the patient about 1-6 hours before subjecting the patient to MRI.
摘要翻译：包括以下顺序步骤：a）提供包含生理上可接受的非螯合锰（II）化合物，生理上可接受的氨基酸和维生素D的造影剂; b）向患者口服或胃部施用造影剂; 以及c）在施用造影剂后约1-6小时使患者对肝脏进行磁共振成像（MRI）。如上所述的对比剂，用于在患者进行MRI前约1-6小时给予患者肝脏的肝脏检查。使用生理上可接受的非螯合锰（II）化合物，生理学上可接受的氨基酸和维生素D来制造造影剂，用于通过在约1-6小时前向患者给予人类肝脏的肝脏患者进行MRI检查。

63. 发明申请

WO2010067076A3 PULSE SEQUENCING WITH HYPERPOLARISABLE NUCLEI 审中-公开
标题翻译：具有超可逆核的脉冲序列
公开(公告)号：WO2010067076A3
公开(公告)日：2010-09-10
申请号：PCT/GB2009002860
申请日：2009-12-10
申请人： UNIV YORK , DUCKETT SIMON BENEDICT , GREEN GARY GEORGE REGINALD , COWLEY MICHAEL JAMES
发明人： DUCKETT SIMON BENEDICT , GREEN GARY GEORGE REGINALD , COWLEY MICHAEL JAMES
IPC分类号： G01R33/28 , A61K49/06 , C07F15/00 , G01R33/46
CPC分类号： G01R33/5601 , A61K49/10 , C07F15/0033 , C07F15/004 , G01R33/282 , G01R33/4608 , G01R33/5605 , G01R33/5607 , Y10T436/24
摘要： There is described a method of selective observation of non-hydrogenative para- hydrogen induced polarisation (NH-PHIP) as enhanced magnetic resonance signals which comprises separating the thermal and longitudinal spin order states. There is also described a template comprising [Ir(COD)(NHC)(Py)]+, and analogues thereof, for use in a PHIP magnetic resonance technique and a method for its preparation.
摘要翻译：描述了一种选择性地观察非氢化对 - 氢激发极化（NH-PHIP）作为增强的磁共振信号的方法，其包括分离热和自旋有序状态。还描述了包含[Ir（COD）（NHC）（Py）] +的模板及其类似物，用于PHIP磁共振技术及其制备方法。

64. 发明申请

WO2010048768A1 硝咪唑-氨基酸化合型核素乏氧造影剂及其前体审中-公开
公开(公告)号：WO2010048768A1
公开(公告)日：2010-05-06
申请号：PCT/CN2009/000246
申请日：2009-03-09
申请人：阮建评
发明人：阮建评
IPC分类号： C07D233/91 , C07D233/92 , C07D233/95 , A61K49/06 , A61K51/00 , A61K51/04 , A61K51/08
CPC分类号： A61K51/0497 , A61K51/0453 , C07D233/92 , C07D233/95 , C07F13/005

65. 发明申请

WO2010046796A1 MOLECULAR IMAGING 审中-公开
标题翻译：分子成像
公开(公告)号：WO2010046796A1
公开(公告)日：2010-04-29
申请号：PCT/IB2009/054370
申请日：2009-10-06
申请人： KONINKLIJKE PHILIPS ELECTRONICS, N.V. , U.S. PHILIPS CORPORATION , CARMI, Raz , KAFRI, Galit, Sarit
发明人： CARMI, Raz , KAFRI, Galit, Sarit
IPC分类号： A61B6/03 , A61K49/04 , A61K49/06 , A61K51/00
CPC分类号： A61K49/0414 , A61B6/037 , A61B6/4014 , A61B6/4035 , A61B6/4241 , A61B6/482 , A61K49/126 , A61K49/1887 , A61K51/1244
摘要： An imaging system includes a radiation source (110) that emits radiation that traverses an examination region and a detector (116) that detects radiation traversing the examination region and a subject disposed therein, and produces a signal indicative of the energy of the detected radiation. A data selector (122) energy discriminates the signal based on an energy spectra setting corresponding to first and second spectral characteristics of a contrast agent administered to the subject, wherein the contrast agent has a first attenuation spectral characteristic when attached to the target and a second different spectral characteristic when not attached to the target. A reconstructor (134) reconstructs the signal based on the first and second spectral characteristics and generates volumetric image data indicative of the target.
摘要翻译：成像系统包括发射穿过检查区域的辐射的辐射源（110）和检测穿过检查区域的辐射的检测器（116）以及设置在其中的对象，并且产生指示检测到的辐射的能量的信号。数据选择器（122）基于对应于施用于对象的造影剂的第一和第二光谱特性的能谱设置来对信号进行鉴别，其中造影剂当附着到靶时具有第一衰减光谱特性，不附加到目标时的不同光谱特性。重构器（134）基于第一和第二光谱特征重建信号，并产生指示目标的体积图像数据。

66. 发明申请

WO2009155335A3 CONJUGATES OF 19F MR IMAGING TRACERS AND CHEMOTHERAPEUTIC AGENTS FOR DRUG QUANTIFICATION AND DRUG DOSE INDIVIDUALIZATION 审中-公开
公开(公告)号：WO2009155335A3
公开(公告)日：2009-12-23
申请号：PCT/US2009/047648
申请日：2009-06-17
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , UNIVERSITY OF MARYLAND, COLLEGE PARK , YU, Yihua
发明人： YU, Yihua
IPC分类号： A61K49/06 , A61K31/513 , A61P35/00 , A61K47/48
摘要： A therapeutic agent formed of a magnetic resonance imaging tracer conjugated with a chemotherapeutic agent. The therapeutic agents can be used in measuring drug delivery to a target tissue. The therapeutic agents allow for therapeutic MRI, in which 19 F MRI techniques are used to detect, monitor, evaluate, and/or adjust chemotherapeutic drug dosage levels in a patient or a targeted tissue thereof.

67. 发明申请

WO2009154425A2 MULTIMODAL IMAGING METHOD USING NANO-EMULSION COMPRISING OPTICAL NANO-PARTICLES AND PERFLUOROCARBONS 审中-公开
标题翻译：使用包含光学纳米颗粒和全氟化碳的纳米乳液的多模式成像方法
公开(公告)号：WO2009154425A2
公开(公告)日：2009-12-23
申请号：PCT/KR2009/003308
申请日：2009-06-19
申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY , CHUNG, Bong Hyun , LIM, Yong Taik
发明人： CHUNG, Bong Hyun , LIM, Yong Taik
IPC分类号： A61K49/06
CPC分类号： A61K49/0078 , A61K49/0002 , A61K49/0017 , A61K49/0067 , A61K49/1806
摘要： The present invention relates to a multimodal imaging method using a nano-emulsion comprising optical nano-particles and perfluorocarbons, and more particularly, to a method of obtaining multimodal images using a nano-emulsion consisted of perfluorocarbons for multispectral magnetic resonance imaging (MRI) and nano-particles for multicolor fluorescent detection. In the multimodal imaging method, various multispectral MRI images and multicolor fluorescent rays can be obtained by varing the kind and combination of perfluorocarbons and the kind and combination of optical nano-particles, so that multiplexed analysis is possible. Accordingly, the multimodal imaging method can be applied to various fields, including biological and medical fields in which studies on cell molecular imaging has been conducted.
摘要翻译：本发明涉及一种使用包含光学纳米颗粒和全氟化碳的纳米乳液的多模式成像方法，更具体地说，涉及使用由全氟化碳构成的纳米乳液用于多光谱磁共振成像（MRI）和用于多色荧光检测的纳米颗粒。在多模式成像方法中，可以通过改变全氟化碳的种类和组合以及光学纳米颗粒的种类和组合来获得各种多光谱MRI图像和多色荧光光谱，从而可以进行多重分析。因此，多模式成像方法可以应用于已经进行细胞分子成像研究的生物和医学领域的各个领域。

68. 发明申请

WO2009103744A3 PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST AGENTS 审中-公开
标题翻译：制备药物制剂的方法
公开(公告)号：WO2009103744A3
公开(公告)日：2009-12-17
申请号：PCT/EP2009051937
申请日：2009-02-18
申请人： GUERBET SA , MEYER DOMINIQUE , COROT CLAIRE , PORT MARC , BARBOTIN VINCENT , BONNEMAIN BRUNO
发明人： MEYER DOMINIQUE , COROT CLAIRE , PORT MARC , BARBOTIN VINCENT , BONNEMAIN BRUNO
IPC分类号： A61K49/06
CPC分类号： A61K49/108 , A61K9/0019 , A61K31/28 , A61K45/06 , A61K47/18 , A61K49/106 , G01N33/15
摘要： The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount offree macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C chl and/or of free lanthanide C lanl; d)adjustmentof C chl and/or of C lanl so as to obtain C chl = C tchl and C lanl = 0, wherein C t chl is the target concentration of free macrocyclic chelate in the final liquid pharmaceuticalformulation.
摘要翻译：本发明涉及一种制备液体药物制剂的方法，其含有大环螯合物与镧系元素的复合物和摩尔/摩尔量的大分子螯合物，其含量为0.002％至0.4％，有利地为0.02％至0.3％，非常有利地为0.025 ％和0.25％，大环螯合物有利地选自DOTA，NOTA，DOTAGA，DO3A，BT-DO3A，HP-DO3A和PCTA，并且优选为DOTA，所述方法包括以下连续步骤：b）制备液体药物组合物首先含有大环螯合物与镧系元素的复合物，其次，游离的大环螯合物和/或游离镧系元素; c）在步骤b）中获得的药物制剂中测量游离大环螯合物C ch1和/或游离镧系元素C lanl的浓度; d）调整C chl和/或C lanl，以获得C chl = C tchl和C lanl = 0，其中C t chl是游离大环螯合物在最终液体药物制剂中的目标浓度。

69. 发明申请

WO2009146153A2 MANUFACTURE, TRANSPORT AND DELIVERY OF MATERIAL CONTAINING HIGHLY POLARIZED NUCLEI 审中-公开
标题翻译：制造，运输和运送包含高极化核的材料
公开(公告)号：WO2009146153A2
公开(公告)日：2009-12-03
申请号：PCT/US2009/039696
申请日：2009-04-06
申请人： MILLIKELVIN TECHNOLOGIES LLC , KALECHOFSKY, Neal , BELZER, Avrum
发明人： KALECHOFSKY, Neal , BELZER, Avrum
IPC分类号： A61K49/06 , A61K47/02 , A61K47/12 , A61P43/00 , G01N24/08
CPC分类号： A61K49/10 , G01R33/282 , G01R33/5601
摘要： The present disclosure provides various methods and systems for manufacture, transport and delivery of material including highly polarized nuclei that is in a hyperpolarized state.
摘要翻译：本公开提供了用于制造，输送和输送包括处于超极化状态的高度极化的核的材料的各种方法和系统。

70. 发明申请

WO2009100014A1 SYSTEM FOR FLUORINATING ORGANIC COMPOUNDS 审中-公开
标题翻译：氟化有机化合物系统
公开(公告)号：WO2009100014A1
公开(公告)日：2009-08-13
申请号：PCT/US2009/032855
申请日：2009-02-02
申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE , RITTER, Tobias , FURUYA, Takeru , KAISER, Hanns, M.
发明人： RITTER, Tobias , FURUYA, Takeru , KAISER, Hanns, M.
IPC分类号： A61K31/00 , A61K49/06 , A61K51/04 , C07D489/00 , C07F15/00
CPC分类号： B01J31/2295 , A61K49/06 , C07C17/093 , C07C29/62 , C07C37/62 , C07C41/22 , C07C45/63 , C07C53/10 , C07C231/12 , C07D209/08 , C07D221/06 , C07D307/82 , C07F15/0066 , C07C33/46 , C07C39/27 , C07C43/225
摘要： Described herein are fluorinated organic compounds and methods of making fluorinated organic compounds, for example, using palladium complexes. Also described herein are compositions and kits containing compounds and palladium complexes described herein.
摘要翻译：本文描述了氟化有机化合物和制备氟化有机化合物的方法，例如使用钯络合物。本文还描述了包含本文所述的化合物和钯络合物的组合物和试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式